Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRSW117 in severe hemophilia A PK and safety study
CTR20220283Phase 2Completed
- Sponsor
- Shengsi Biopharmaceutical
- Start
- Feb 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated recombinant human coagulation factor VIII-Fc fusion protein in hemophilia A, sponsored by Shengsi Biopharmaceutical. Started Feb 2022; status: completed.
02
Drugs
pegylated recombinant human coagulation factor VIII-Fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20220283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220283.